4-溴-5-苯基-1H-1,2,3-三唑 | 21505-14-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-溴-5-苯基-1H-1,2,3-三唑
• 英文名称: 4-bromo-5-phenyl-2H-1,2,3-triazole
• 英文别名: 4-Bromo-5-phenyl-1H-1,2,3-triazole；4-bromo-5-phenyl-2H-triazole
• CAS: 21505-14-6
• 化学式: C₈H₆BrN₃
• 分子量: 224.06
• InChiKey: JHODODBNOMARQV-UHFFFAOYSA-N

物化性质

• 沸点：
  377.4±22.0 °C(Predicted)
• 密度：
  1.651±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• WGK Germany：
  3
• 海关编码：
  2933990090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 4-Bromo-5-phenyl-1H-1,2,3-triazole
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 21505-14-6
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Chemical characterization : Natural product
Formula : C8H6BrN3
Molecular Weight : 224,06 g/mol
CAS-No. : 21505-14-6
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
4-Bromo-5-phenyl-1H-1,2,3-triazole
CAS-No. 21505-14-6 Acute Tox. 4; H302 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
4-Bromo-5-phenyl-1H-1,2,3-triazole
CAS-No. 21505-14-6 Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen bromide gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Z677272, Size M)
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone [phone] test method: EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374,
contact the supplier of the CE approved gloves. This recommendation is advisory only and must
be evaluated by an industrial hygienist and safety officer familiar with the specific situation of
anticipated use by our customers. It should not be construed as offering an approval for any
specific use scenario.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: Powder with lumps
Colour: white
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing 153 - 154 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,241
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H302 Harmful if swallowed.
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R22 Harmful if swallowed.
Further information
Copyright 2013 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  4-溴-5-苯基-1H-1,2,3-三唑 在 dipotassium peroxodisulfate 、 palladium 10% on activated carbon 、 氢气 、 copper diacetate 、 sodium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N-methyl-N-((4-phenyl-2H-1,2,3-triazol-2-yl)methyl)formamide
  参考文献：
  名称：

  铜催化的交叉脱氢Ñ 2的-耦合NH -1,2,3-三唑与Ñ，Ñ：-Dialkylamides Ñ的-Amidoalkylation NH -1,2,3-三唑

  摘要：

  已经开发了通过NH -1,2,3-三唑与N，N-二烷基酰胺之间的NH - CH / CH-H交叉脱氢偶联（CDC）形成有效的铜催化C-N键的方法。该方法提供了中等至高产率的N-酰胺基烷基化的1,2,3-三唑，并且当以4,5-二取代的NH -1,2,3-三唑为底物时，反应显示出高的N 2-选择性。

  DOI：

  10.1021/acs.joc.7b00752
• 作为产物：
  描述：

  4-羟甲基苯甲酸 在 1-羟基苯并三唑 、 N,N'-二异丙基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 4-溴-5-苯基-1H-1,2,3-三唑
  参考文献：
  名称：

  通过苯胺脱氨制得氘代芳烃的有效途径

  摘要：

  据报道，氘能一步取代环取代苯胺中的NH 2基团。包括固相合成和溶液相合成的方法都可以用于多种基质上。该方法在水和二氯甲烷或氯仿的混合物中使用重氮化作用，而二氯甲烷或氯仿是氢的来源。该方案可以用作使用氘化氯仿将氘快速轻松地掺入芳族体系的一般方法。

  DOI：

  10.1021/acs.orglett.6b01438

文献信息

• Design, synthesis and evaluation of β-lactam antigenic peptide hybrids; unusual opening of the β-lactam ring in acidic media
  作者：Marion Tarbe、Itxaso Azcune、Eva Balentová、John J. Miles、Emily E. Edwards、Kim M. Miles、Priscilla Do、Brian M. Baker、Andrew K. Sewell、Jesus M. Aizpurua、Céline Douat-Casassus、Stéphane Quideau

  DOI：10.1039/c003877f

  日期：——

  β-Lactam peptides were envisioned as conformational constraints in antigenic peptides (APs). Three different β-lactam tripeptides of varying flexibility were prepared in solution and incorporated in place of the central part of the altered melanoma associated antigenic peptide Leu27-Melan-A26–35 using solid phase synthesis techniques. Upon TFA cleavage from the solid support, an unexpected opening of the β-lactam ring occurred with conservation of the amide bond. After adaptation of the solid phase synthesis strategy, β-lactam peptides were successfully obtained and both opened and closed forms were evaluated for their capacity to bind to the antigen-presenting class-I MHC HLA-A2 protein system. None of the closed β-lactam peptides bound to HLA-A2, but their opened variants were shown to be moderate to good HLA-A2 ligands, one of them being even capable of stimulating a Melan-A-specific T cell line.

  设想β-内酰胺肽在抗原肽(APs)中作为构象约束。通过溶液制备了三种不同灵活性的β-内酰胺三肽，并采用固相合成技术将其取代改变的黑色素瘤相关抗原肽Leu27-Melan-A26-35的中心部分。在TFA从固相支持物切割后，发生了意外的β-内酰胺环打开，同时保留了酰胺键。在固相合成策略的适应之后，成功获得了β-内酰胺肽，并且评估了它们的打开和关闭形式与抗原呈递I类MHC HLA-A2蛋白系统的结合能力。没有任何封闭的β-内酰胺肽与HLA-A2结合，但它们的打开变体显示出从中等到良好的HLA-A2配体能力，其中一个甚至能够刺激Melan-A特异性T细胞系。
• A convenient procedure for the solid-phase synthesis of hydroxamic acids on PEGA resins
  作者：Nitin S. Nandurkar、Rico Petersen、Katrine Qvortrup、Vitaly V. Komnatnyy、Kennedy M. Taveras、Sebastian T. Le Quement、Robin Frauenlob、Michael Givskov、Thomas E. Nielsen

  DOI：10.1016/j.tetlet.2011.10.103

  日期：2011.12

  An efficient method for the solid-phase synthesis of hydroxamic acids is described. The method comprises the nucleophilic displacement of esters immobilized on PEGA resins with hydroxylamine/sodium hydroxide in isopropanol. The hydroxyaminolysis protocol is compatible with a broad range of PEGA-supported peptide and peptidomimetic esters. The methodology was found to be compatible with two new strategies

  描述了一种固相合成异羟肟酸的有效方法。该方法包括用羟胺/氢氧化钠在异丙醇中固定在PEGA树脂上的酯进行亲核取代。羟氨解方案可与多种PEGA支持的肽和拟肽酯相容。发现该方法与分别用于合成固载内酰胺和二酮哌嗪的两种新策略兼容，二者均依赖于环状N-酰基亚胺离子与富电子芳族化合物和杂芳族化合物的高分子间和分子内反应性，最终提供了高纯度的异羟肟酸衍生物。
• Macrocyclic hepatitis C serine protease inhibitors
  申请人：Miao Zhenwei

  公开号：US20050153877A1

  公开（公告）日：2005-07-14

  The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I、II或III的化合物，或其药用可接受的盐、酯或前药： 其中W是取代或未取代的杂环环系。这些化合物抑制丝氨酸蛋白酶活性，尤其是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还可用作抗病毒剂。本发明进一步涉及包含上述化合物的药物组合物，用于给患有HCV感染的对象进行给药。本发明还涉及通过给主体投药包含本发明化合物的药物组合物来治疗主体HCV感染的方法。
• Facile and direct halogenation of 1,2,3-triazoles promoted by a KX–oxone system under transition metal free conditions
  作者：Vishakha Rai、Ganesh Shivayogappa Sorabad、Mahagundappa Rachappa Maddani

  DOI：10.1039/d0nj05170e

  日期：——

  A convenient and efficient oxidative halogenation of 4-aryl 1,2,3-triazoles is realized at ambient temperature under transition metal free conditions.

  在无过渡金属条件下，可以在常温下方便高效地对4-芳基1,2,3-三唑进行氧化卤化。
• [EN] SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE<br/>[FR] DÉRIVÉS DE 1,3-PHÉNYL HÉTÉROARYLE SUBSTITUÉS ET LEUR UTILISATION DANS LE TRAITEMENT D'UNE MALADIE
  申请人：NOVARTIS AG

  公开号：WO2021038426A1

  公开（公告）日：2021-03-04

  The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the ctivity of TMEM16a. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including COPD, bronchiectasis, asthma, cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, cystic fibrosis, primary ciliary dyskinesia, respiratory tract infections (acute and chronic; viral and bacterial), lung carcinoma.

  该发明涉及公式（I）中的杂环化合物，其中所有变量均如规范中定义；能够调节TMEM16a的活性。该发明进一步提供了一种制造该发明化合物的方法及其治疗用途。该发明还提供了它们的制备方法，医学用途，特别是在治疗和管理包括COPD、支气管扩张、哮喘、囊性纤维化、原发性纤毛运动障碍、慢性支气管炎、肺部感染（急性和慢性；病毒和细菌性）、肺癌等疾病或疾病的用途。